updat solid result like point bright
solid result driven execut new product launch
solid exist portfolio perform chca chci front off-set
neg pressur rx segment follow call continu faith
abil deliv grow revenu addit new product launch
continu execut maintain buy rate pt
total revenu modestli ahead estim gener modest disappoint
rel street consolid revenu bn bn
consensu bn chca revenu mm consensu
mm chci revenu mm mm consensu mm
gener revenu mm mm consensu mm
gener still challeng appear portfolio-driven peer see futur
strength revis guidanc rx segment revenu bn
bn due prevail neg market condit believ
like portfolio-driven peer space note type stability/
predict price neg pressur like off-set new
product introduct continu expect proair launch ep contribut
expect addit strong launch rx next three quarter
launch flow bias back half year manag expect
rx revenu captur
chca chci perform driven execut strength chca driven
particularli strong perform infant nutrit cough/cold segment
somewhat off-set weaker anim health sale continu gain store brand
share expect launch increment new product cours year chca
outlook unchang previou guidanc bn sale
oper margin chci segment strength driven continu execut
region brand new product revenu guidanc revis bn
bn addit chci oper margin expect expand
bp previou guidanc manag note strong chci oper margin
perform like repeat year plan reinvest
sale infrastructur long-term margin expans
modestli adjust estim perform given continu confid
reinvest chci addit share gain launch chca accret
product launch rx segment see solid year ahead
adjust estim maintain buy rate pt
perrigo compani plc focus develop
distribut private-label gener brand over-the-counter
prescript drug private-label nutrit product
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
total revenu modestli ahead estim gener modest disappoint
rel street
consolid revenu bn bn consensu
bn chca revenu mm consensu mm chci
revenu mm mm consensu mm gener revenu
mm mm consensu mm
figur perrigo financi perform cgie consensu
chang estim
follow public compani result modestli updat
revenu ep estim
figur chang revenu ep estim
price target deriv dcf consid wacc
risk rate price target
long-term chca growth depend rx-to-otc shift new categori
usual drive low-single-digit growth consum health america
chca busi though increas privat label uptak off-set somewhat retail
price pressur believ signific sustain growth chca busi
driven addit categori switch prescript over-the-counter condit
littl control brand pharma compani fda
resist move statin topic pain nsaid overact bladder treatment
erectil dysfunct product migrain product asthma inhal ophthalm
allergi dry-ey treatment over-the-counter could see pressur chca segment
despit domin share chca addit competitor start gain
long held domin share private-label over-the-counter market recent
over-the-counter switch seen steadi competit tradit prescript gener
compani seek gain traction over-the-counter retail typic assumpt
share given pl over-the-counter market longer guarante
believ continu increment competit could significantli slow perrigo
consum health intern chci busi may prove drag
take correct action segment follow challeng
belgian busi believ growth could slow segment follow brexit
potenti fx challeng continu restructur busi
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
million usd except per share non-gaaprevenueconsum healthcar healthcar profit oper expensescost ipr oper expensestysabri chang expens expense/ incom sale invest -- -- -- -- -- -loss extinguish non-oper net incomeincom tax analysisbas per share share figur perrigo dcf model
million usd except per share healthcar healthcar depreci amort exclud chang growth estim period long-term period net debt share outstand compani
